Arrowhead Pharmaceuticals (ARWR)
Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.
$71.86
After hours+0.03 (+0.04%)
At close$71.83(+4.42%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 83.14% | 117.44M shares | |
|---|---|---|---|
| 523 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.32% | 1.86M shares | |
| 13 holders · as of Aug 20, 2026 | |||
| Other | ≈ 15.54% | 21.95M shares | |
| remainder | |||
141.25M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
13F, as of Jun 30, 2026
523 holders · 117.44M shares · 126 new positions · 282 increased · 162 reduced · 62 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 14.83M | 10.50% | −3.33M | Aug 7, 2026 |
| Avoro Capital Advisors LLC | 11.36M | 8.04% | +655.6K | Aug 14, 2026 |
| FMR LLC | 8.04M | 5.69% | +773.2K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 6.35M | 4.50% | −794.8K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.11M | 4.33% | +78.5K | Aug 13, 2026 |
| State Street Corp | 5.69M | 4.03% | −801.5K | Aug 7, 2026 |
| Norges Bank | 3.90M | 2.76% | +3.90Mnew | Aug 12, 2026 |
| Invesco Ltd. | 3.88M | 2.75% | +603.3K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 12.20% | 17.10M | 13G | Apr 24, 2026 |
| Avoro Capital Advisors LLC | 8.30% | 11.52M | 13G | Aug 14, 2025 |
| FMR LLC | 5.20% | 7.35M | 13G | May 6, 2026 |
| Vanguard Portfolio Management | 5.19% | 7.27M | 13G | Apr 28, 2026 |
| State Street Corporation | 5.10% | 6.35M | Oct 16, 2024 | |
| Vanguard Capital Management | 5.05% | 7.08M | 13G | Apr 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Y. Olukotundirector | Sale | 2,000 | $86.96 | 31,600 |
| Aug 18, 2026 | Michael S. Perrydirector | Sale | 11,600 | $87.30 | 111,459 |
| May 12, 2026 | Hongbo Ludirector | Sale | 2,970 | $76.88 | 52,012 |
| Apr 23, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale | 10,000 | $75.00 | 226,958 |
| Apr 22, 2026 | Daniel Joseph Apelofficer: Chief Financial Officer | Sale · 3 lots | 13,095 | $71.35 | 162,905 |
| Mar 5, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale | 10,000 | $64.19 | 236,958 |
| Jan 2, 2026 | Christopher Richard Anzalonedirector, officer: Chief Executive Officer | Sale · 2 lots | 13,187 | $66.10 | 3,792,739 |
| Jan 5, 2026 | James C. Hamiltonofficer: Chief Medical Officer | Sale · 7 lots | 40,164 | $63.11 | 171,958 |
| Jan 5, 2026 | Patrick O'Brienofficer: COO | Sale · 12 lots | 49,493 | $63.11 | 474,908 |
| Dec 26, 2025 | Mauro Ferraridirector | Sale | 7,530 | $70.00 | 69,053 |
House and Senate disclosures
Not reported.